MNMD Similar Chart Price Prediction
The price of MNMD is predicted to go up -21.93%, based on the high correlation periods with AEON. The similarity of these two price pattern on the periods is 95.23%.
MNMD
AEON
Down: -21.93%Similarity: 95.23%
MNMD Revenue Forecast
MNMD EPS Forecast
MNMD Analyst's Forecast
Rudy Li
Chardan Capital
Strong Buy
2024-12-20
Price Target
$20
Upside
+179.33%
Chardan initiated coverage of Mind Medicine with a Buy rating and $20 price target. The firm cites the potential of the company's lead asset MM120 for the treatment of generalized anxiety disorder and major depressive disorder for its Buy rating. Its thesis assumes MM120 will report positive data in 2026 and deliver a solid commercial launch with over $1B in peak sales. Chardan expects the sentiment on the shares to continue to improve moving into 2025 with multiple key catalyst events.
